Starling Oncology vs GeneDx
Starling Oncology reported revenue of $503 million in fiscal 2025, 1.2 times GeneDx's $428 million in fiscal 2025. Starling Oncology's revenue grew 27.8% in its latest year, and GeneDx's grew 40.0%. Starling Oncology had an operating margin of -7.2%, against -3.1% at GeneDx. Free cash flow was −$28 million at Starling Oncology and $14 million at GeneDx.
Side by side
| Starling Oncology | GeneDx | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $503M | $428M |
| Revenue growth | 27.8% | 40.0% |
| Revenue growth a year, last 5 years | 21.8% | 19.0% |
| Gross margin | — | 69.7% |
| Operating margin | −7.2% | −3.1% |
| Net margin | −12.1% | −4.9% |
| Free cash flow | −$28M | $14M |
| Free cash flow margin | −5.5% | 3.3% |
| Return on capital | −75.7% | −5.3% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.1% | 6.5% |
| Last close | $3.50 | $52.37 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $106.6 million, sold $21.5 million |
| Piotroski F-score | 3 of 8 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Starling OncologyGeneDx
Operating margin
Percent of revenue
Starling OncologyGeneDx
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Starling OncologyGeneDx
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Starling Oncology and GeneDx pages.